Ask AI
GI Cancer Highlights From ASCO 2026

CE / CME

Gastrointestinal Cancer Highlights From ASCO 2026: Expert Perspectives on Emerging Practice-Changing Data

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 30, 2026

Expiration: January 29, 2027

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with gastrointestinal cancers do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following patients with advanced pancreatic cancer would you consider a candidate for daraxonrasib therapy if this drug is approved based on the findings of the phase III RASolute-302 trial reported by Wolpin and colleagues at the 2026 ASCO annual meeting?

4.

Which of the following findings was reported from the phase III FIGHT-302 trial that compared pemigatinib vs chemotherapy as first-line therapy in patients with unresectable advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement?

5.

How likely are you to incorporate daraxonrasib into your practice for patients with advanced pancreatic cancer once it is approved?